Diff Diag of parkinson's Disease, Multiple Sys Atrophy, & Steele-Richardson-Olszewski Syndrome:Striatal F-Dopa PET Data
JNNP 57:278-284, Burn,D.J.,et al, 1994
Four-Year Follow-up of Adrenal-to-Brain Transplants in Parkinson's Disease
Arch Neurol 51:559-563, Diamond,S.G.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Therapy of Patients with Parkinson's Disease
Arch Neurol 51:754-756, Paulson,G.W., 1994
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Parkinsonism Caused by Petroleum Waste Ingestion
Neurol 44:1051-1054, Tetrud,J.W.,et al, 1994
Preliminary NINDS Neuropathologic Criteria for Steele-Richardson-Olszewski Syndrome (Progressive Supranuclear Palsy)
Neurol 44:2015-2019, Hauw,J.-J., 1994
Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993
Autosomal Dominant Parkinsoniam with Benign Course and Typical Lewy-Body Pathology
Neurol 43:2222-2227, Golbe,L.I.,et al, 1993
Risk Factors for Nursing Home Placement in Advanced Parkinson's Disease
Neurol 43:2227-2229, Goetz,C.G.&Stebbins,G.T., 1993
Fatigue in Parkinson's Disease
Neurol 43:2016-2018, Friedman,J.&Friedman,H., 1993
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Aspartame Use in Parkinson's Disease
Neurol 43:611-613, Karstaedt,P.J.&Pincus,J.H., 1993
Nigral Dysfunction in Drug-Induced Parkinsonism:An F-dopa PET Study
Neurol 43:552-556, Burn,D.J.&Brooks,D.J., 1993
Prognostic Significance of the Onset Mode in Parkinsonism
Neurol 43:829-830, Rajput,A.H.,et al, 1993
PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993
Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease
Arch Neurol 50:721-724, Hutton,J.T.,et al, 1993
T2 Relaxation Time in Patients with Parkinson's Disease
Neurol 43:697-700, Antonini,A.,et al, 1993
The Spectrum of Levodopa-Related Fluctuations in Parkinson's Disease
Neurol 43:1459-1464, Riley,D.E.&Lang,A.E., 1993
Contrast Agent Overdose Causing Brain Retention of Contrast, Seizures, and Parkinsonism
Neurol 43:836-838, May,E.F.,et al, 1993
Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993
Clinicopath Conf
progressive Supranuclear Palsy, Case 46-1993, NEJM 329:1560-1567993., , 1993
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Movement Disorders with Cerebral Toxoplasmosis and AIDS
Movement Disorders 8:107-112, Nath,A.,et al, 1993
Neurosurgical Horizons in Parkinson's Disease
Neurol 43:1-7, Goetz,C.G.,et al, 1993
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Subcortical Dementia
BMJ 307:1-2, Dunne,F.J., 1993
The Prevalence of Metoclopramide-Induced Tardive Dyskinesia and Acute Extrapyramidal Movement Disorders
Arch Int Med 153:1469-1475, Ganzini,L.,et al, 1993
Progression After Chronic Manganese Exposure
Neurol 43:1479-1483, Huang,C.C.,et al, 1993
Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
Levodopa, Melanoma, and Parkinson's Disease
Neurol 43:674-677, Weiner,W.J.,et al, 1993
Comparison of Striatal 18F-dopa Uptake in Adult-Onset Dystonia-Parkinsonism, Parkinson's & Dopa-Responsive Dystonia
Neurol 43:1563-1568, Turjanski,N.,et al, 1993
Identical Twins with Similar Onset of Parkinson's Disease:A Case Report
Neurol 43:1159-1161, Pahwa,R.,et al, 1993
Parkinson's Disease:A Test of the Multifactorial Etiologic Hypothesis
Neurol 43:1173-1180, Semchuk,K.M.,et al, 1993
Environmental Causation of Parkinson's Disease
Arch Neurol 50:651-652, Rajput,A.H., 1993
The Nonenvironmental Basis for Rising Mortality from Parkinson's Disease
Arch Neurol 50:653-656, Riggs,J.E., 1993
Risk Factors for Parkinson's Disease
Neurol 43:1693-1697, 16411993., Hubble,J.P.,et al, 1993
Environmental Antecedents of Young-Onset Parkinson's Disease
Neurol 43:1150-1158, Butterfield,P.G.,et al, 1993
Olfactory Testing Differentiates Between Progressive Supranuclear Palsy & Idiopathic Parkinson's Dis
Neurol 43:962-965, Doty,R.L.,et al, 1993
Defecatory Function in Parkinson's Disease:Response to Apomorphine
Ann Neurol 33:490-493, Edwards,L.L.,et al, 1993
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Faithful Fashion:Survival Status of the Brain Transplant Cure for Parkinsonism
Neurol 43:644-649, Landau,W.M., 1993
Practice Parameters:Initial Therapy of Parkinson's Disease
Report of the Quality Standards Subcommittee of AAN, Neurol 43:1296-12971993., , 1993
Clinical Experience with Controlled-Release Carbidopa/Levodopa in Parkinson's Disease
Neurol 43:677-681, Pahwa,R.,et al, 1993
Clinical and Magnetic Resonance Features of the Classic & Akinetic-Rigid Variants of Huntington's Dis
Arch Neurol 50:17-19, Oliva,D.,et al, 1993
Parkinsonism Unmasked by Verapamil
Clinical Neuropharmacol 16:263-265, Garcia-Albea,E.,et al, 1993
Mitochondrial Involvement in Parkinson's Disease:The Controversy Continues
Neurol 43:2170-2172, DiMauro,S., 1993
The Motor Disorder of Multiple System Atrophy
JNNP 56:1239-1242, Quinn,N.P.&Marsden,C.D., 1993